These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 17325706)

  • 1. Anti-inflammatory agents and monoHER protect against DOX-induced cardiotoxicity and accumulation of CML in mice.
    Bruynzeel AM; Abou El Hassan MA; Schalkwijk C; Berkhof J; Bast A; Niessen HW; van der Vijgh WJ
    Br J Cancer; 2007 Mar; 96(6):937-43. PubMed ID: 17325706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The influence of the time interval between monoHER and doxorubicin administration on the protection against doxorubicin-induced cardiotoxicity in mice.
    Bruynzeel AM; Mul PP; Berkhof J; Bast A; Niessen HW; van der Vijgh WJ
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):699-702. PubMed ID: 16565833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term effects of 7-monohydroxyethylrutoside (monoHER) on DOX-induced cardiotoxicity in mice.
    Bruynzeel AM; Vormer-Bonne S; Bast A; Niessen HW; van der Vijgh WJ
    Cancer Chemother Pharmacol; 2007 Sep; 60(4):509-14. PubMed ID: 17177067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparative study between catalase gene therapy and the cardioprotector monohydroxyethylrutoside (MonoHER) in protecting against doxorubicin-induced cardiotoxicity in vitro.
    Abou-El-Hassan MA; Rabelink MJ; van der Vijgh WJ; Bast A; Hoeben RC
    Br J Cancer; 2003 Dec; 89(11):2140-6. PubMed ID: 14647150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monohydroxyethylrutoside, a dose-dependent cardioprotective agent, does not affect the antitumor activity of doxorubicin.
    van Acker SA; Boven E; Kuiper K; van den Berg DJ; Grimbergen JA; Kramer K; Bast A; van der Vijgh WJ
    Clin Cancer Res; 1997 Oct; 3(10):1747-54. PubMed ID: 9815559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The protective effect of cardiac gene transfer of CuZn-sod in comparison with the cardioprotector monohydroxyethylrutoside against doxorubicin-induced cardiotoxicity in cultured cells.
    Abou El Hassan MA; Heijn M; Rabelink MJ; van der Vijgh WJ; Bast A; Hoeben RC
    Cancer Gene Ther; 2003 Apr; 10(4):270-7. PubMed ID: 12679799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monohydroxyethylrutoside as protector against chronic doxorubicin-induced cardiotoxicity.
    van Acker SA; Kramer K; Grimbergen JA; van den Berg DJ; van der Vijgh WJ; Bast A
    Br J Pharmacol; 1995 Aug; 115(7):1260-4. PubMed ID: 7582554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The new cardioprotector Monohydroxyethylrutoside protects against doxorubicin-induced inflammatory effects in vitro.
    Abou El Hassan MA; Verheul HM; Jorna AS; Schalkwijk C; van Bezu J; van der Vijgh WJ; Bast A
    Br J Cancer; 2003 Jul; 89(2):357-62. PubMed ID: 12865930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of monohydroxyethylrutoside on doxorubicin-induced cardiotoxicity in patients treated for metastatic cancer in a phase II study.
    Bruynzeel AM; Niessen HW; Bronzwaer JG; van der Hoeven JJ; Berkhof J; Bast A; van der Vijgh WJ; van Groeningen CJ
    Br J Cancer; 2007 Oct; 97(8):1084-9. PubMed ID: 17940501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thrombopoietin protects against in vitro and in vivo cardiotoxicity induced by doxorubicin.
    Li K; Sung RY; Huang WZ; Yang M; Pong NH; Lee SM; Chan WY; Zhao H; To MY; Fok TF; Li CK; Wong YO; Ng PC
    Circulation; 2006 May; 113(18):2211-20. PubMed ID: 16651473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liposomal doxorubicin attenuates cardiotoxicity via induction of interferon-related DNA damage resistance.
    Gyöngyösi M; Lukovic D; Zlabinger K; Spannbauer A; Gugerell A; Pavo N; Traxler D; Pils D; Maurer G; Jakab A; Riesenhuber M; Pircher A; Winkler J; Bergler-Klein J
    Cardiovasc Res; 2020 Apr; 116(5):970-982. PubMed ID: 31346605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Klotho attenuated Doxorubicin-induced cardiomyopathy by alleviating Dynamin-related protein 1 - mediated mitochondrial dysfunction.
    Zhuang X; Sun X; Zhou H; Zhang S; Zhong X; Xu X; Guo Y; Xiong Z; Liu M; Lin Y; Zhang M; Liao X
    Mech Ageing Dev; 2021 Apr; 195():111442. PubMed ID: 33539906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 7-monohydroxyethylrutoside protects against chronic doxorubicin-induced cardiotoxicity when administered only once per week.
    van Acker FA; van Acker SA; Kramer K; Haenen GR; Bast A; van der Vijgh WJ
    Clin Cancer Res; 2000 Apr; 6(4):1337-41. PubMed ID: 10778960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erythropoietin protects against doxorubicin-induced cardiomyopathy via a phosphatidylinositol 3-kinase-dependent pathway.
    Kim KH; Oudit GY; Backx PH
    J Pharmacol Exp Ther; 2008 Jan; 324(1):160-9. PubMed ID: 17928571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cardioprotector monoHER does not interfere with the pharmacokinetics or the metabolism of the cardiotoxic agent doxorubicin in mice.
    Abou El Hassan MA; Kedde MA; Zwiers UT; Bast A; van der Vijgh WJ
    Cancer Chemother Pharmacol; 2003 Apr; 51(4):306-10. PubMed ID: 12721758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Caspase-dependent and -independent suppression of apoptosis by monoHER in Doxorubicin treated cells.
    Bruynzeel AM; Abou El Hassan MA; Torun E; Bast A; van der Vijgh WJ; Kruyt FA
    Br J Cancer; 2007 Feb; 96(3):450-6. PubMed ID: 17285121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Absence of thrombospondin-2 increases cardiomyocyte damage and matrix disruption in doxorubicin-induced cardiomyopathy.
    van Almen GC; Swinnen M; Carai P; Verhesen W; Cleutjens JP; D'hooge J; Verheyen FK; Pinto YM; Schroen B; Carmeliet P; Heymans S
    J Mol Cell Cardiol; 2011 Sep; 51(3):318-28. PubMed ID: 21624372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sulforaphane protects the heart from doxorubicin-induced toxicity.
    Singh P; Sharma R; McElhanon K; Allen CD; Megyesi JK; Beneš H; Singh SP
    Free Radic Biol Med; 2015 Sep; 86():90-101. PubMed ID: 26025579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heat shock protein 20 interacting with phosphorylated Akt reduces doxorubicin-triggered oxidative stress and cardiotoxicity.
    Fan GC; Zhou X; Wang X; Song G; Qian J; Nicolaou P; Chen G; Ren X; Kranias EG
    Circ Res; 2008 Nov; 103(11):1270-9. PubMed ID: 18948619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Involvement of advanced glycation end-products, pentosidine and N(epsilon)-(carboxymethyl)lysine, in doxorubicin-induced cardiomyopathy in rats.
    Moriyama T; Kemi M; Okumura C; Yoshihara K; Horie T
    Toxicology; 2010 Jan; 268(1-2):89-97. PubMed ID: 20004697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.